Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.9M Buy
53,700
+16,000
+42% +$5.7M ﹤0.01% 2484
2025
Q4
$12.3M Buy
37,700
+11,600
+44% +$3.68M ﹤0.01% 2884
2025
Q3
$7.37M Buy
26,100
+4,300
+20% +$1.25M ﹤0.01% 3279
2025
Q2
$6.09M Buy
21,800
+7,200
+49% +$2.04M ﹤0.01% 3220
2025
Q1
$4.55M Sell
14,600
-2,900
-17% -$856K ﹤0.01% 3457
2024
Q4
$4.56M Sell
17,500
-396,700
-96% -$118M ﹤0.01% 3534
2024
Q3
$133M Buy
414,200
+377,700
+1,035% +$124M 0.02% 672
2024
Q2
$11.4M Sell
36,500
-22,800
-38% -$6.7M ﹤0.01% 2376
2024
Q1
$16.9M Sell
59,300
-17,200
-22% -$5.03M ﹤0.01% 1990
2023
Q4
$22M Buy
76,500
+51,200
+202% +$14M ﹤0.01% 1800
2023
Q3
$6.8M Buy
25,300
+2,700
+12% +$674K ﹤0.01% 2725
2023
Q2
$5.02M Sell
22,600
-9,600
-30% -$2.23M ﹤0.01% 3104
2023
Q1
$7.78M Sell
32,200
-155,500
-83% -$38.2M ﹤0.01% 2654
2022
Q4
$49.3M Sell
187,700
-143,300
-43% -$38.4M 0.01% 1185
2022
Q3
$74.6M Buy
331,000
+226,800
+218% +$55M 0.02% 842
2022
Q2
$25.4M Buy
104,200
+30,400
+41% +$7.45M 0.01% 1699
2022
Q1
$17.8M Buy
73,800
+28,200
+62% +$6.48M ﹤0.01% 2142
2021
Q4
$10.3M Buy
45,600
+29,200
+178% +$6.16M ﹤0.01% 2735
2021
Q3
$3.49M Sell
16,400
-12,200
-43% -$2.81M ﹤0.01% 3675
2021
Q2
$6.97M Sell
28,600
-148,400
-84% -$36.5M ﹤0.01% 3039
2021
Q1
$44M Sell
177,000
-18,500
-9% -$4.41M 0.01% 1272
2020
Q4
$44.9M Sell
195,500
-9,100
-4% -$2.1M 0.01% 1195
2020
Q3
$52M Buy
204,600
+79,700
+64% +$19.7M 0.01% 969
2020
Q2
$29.5M Buy
124,900
+8,000
+7% +$1.83M 0.01% 1373
2020
Q1
$23.7M Sell
116,900
-39,900
-25% -$8.72M 0.01% 1390
2019
Q4
$37.8M Sell
156,800
-415,500
-73% -$91.6M 0.01% 1360
2019
Q3
$111M Buy
572,300
+28,300
+5% +$5.43M 0.03% 592
2019
Q2
$100M Buy
544,000
+442,700
+437% +$79.3M 0.03% 666
2019
Q1
$19.2M Buy
101,300
+10,700
+12% +$2.04M 0.01% 1905
2018
Q4
$17.6M Buy
90,600
+26,300
+41% +$5.13M 0.01% 1906
2018
Q3
$13.3M Sell
64,300
-82,700
-56% -$16.3M ﹤0.01% 2232
2018
Q2
$27.1M Sell
147,000
-39,000
-21% -$6.9M 0.01% 1660
2018
Q1
$31.7M Sell
186,000
-133,200
-42% -$24.5M 0.01% 1484
2017
Q4
$55.5M Sell
319,200
-622,200
-66% -$110M 0.01% 1212
2017
Q3
$176M Buy
941,400
+609,300
+183% +$108M 0.04% 490
2017
Q2
$57.2M Sell
332,100
-107,500
-24% -$17.5M 0.01% 1148
2017
Q1
$72.1M Sell
439,600
-137,400
-24% -$22.8M 0.02% 971
2016
Q4
$84.4M Buy
577,000
+145,200
+34% +$21.9M 0.02% 895
2016
Q3
$72M Buy
431,800
+63,600
+17% +$10.8M 0.02% 937
2016
Q2
$56M Sell
368,200
-14,400
-4% -$2.24M 0.02% 1034
2016
Q1
$57.4M Sell
382,600
-115,700
-23% -$17.2M 0.02% 1000
2015
Q4
$80.9M Sell
498,300
-255,600
-34% -$40.2M 0.03% 785
2015
Q3
$104M Buy
753,900
+322,900
+75% +$50.9M 0.04% 591
2015
Q2
$66.2M Buy
431,000
+215,100
+100% +$34.5M 0.02% 915
2015
Q1
$34.5M Sell
215,900
-343,900
-61% -$54.2M 0.01% 1367
2014
Q4
$89.2M Buy
559,800
+433,400
+343% +$67.5M 0.03% 731
2014
Q3
$17.8M Sell
126,400
-23,800
-16% -$3.11M 0.01% 1886
2014
Q2
$17.8M Sell
150,200
-89,400
-37% -$10.3M 0.01% 1889
2014
Q1
$29.6M Sell
239,600
-153,900
-39% -$18.7M 0.01% 1449
2013
Q4
$44.9M Sell
393,500
-16,800
-4% -$1.91M 0.01% 1124
2013
Q3
$45.9M Buy
410,300
+91,400
+29% +$9.91M 0.02% 1022
2013
Q2
$31.5M Buy
+318,900
New +$33.1M 0.01% 1203

Other funds holding AMGN

Goldman Sachs's AMGN Position: Q1 2026 in Review

Goldman Sachs reduced its Amgen (AMGN) stake by 6.8% in Q1 2026, selling an estimated $111M and leaving 4,219,989 shares worth $1.48B. The position accounts for 0.17% of the portfolio, ranked #97.

Goldman Sachs first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.01B in Q3 2022. 3,127 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Goldman Sachs held 4,219,989 shares of Amgen worth $1.48B as of Q1 2026.
  • Goldman Sachs sold 310,269 Amgen shares in Q1 2026, an estimated $111M.
  • Amgen made up 0.17% of Goldman Sachs's portfolio in Q1 2026, its #97 holding.
  • Goldman Sachs first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Amgen position peaked at $2.01B in Q3 2022.
  • 3,127 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.